Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP We identified data from eight ...

Association between targeted cancer drug net health benefit and uptake, patient out-of-pocket spending, and total spending. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...

The journey from AML diagnosis to recovery emphasized self-advocacy, emotional resilience, and a positive mindset as crucial elements for survival and healing. Setting personal boundaries and ...

– Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1-m and KMT2A-r AML – – ...

The overall 5-year relative survival rate for AML is about 30%, but this number is an estimate based on a large group of people and does not predict individual outcomes. Younger people with AML tend ...